Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers

Mechanisms of Resistance to KRASG12C Inhibitors

(2021) Victoria Dunnett-Kane et al.   Cancers

Association between smoking history and tumor mutation burden in advanced non-small cell lung cancer

(2021) Xinan Wang et al.   CANCER RESEARCH

mRNA vaccine for cancer immunotherapy

(2021) Lei Miao et al.   Molecular Cancer

KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation

(2021) Timothy H. Tran et al.   Nature Communications

C0818, a novel curcumin derivative, induces ROS-dependent cytotoxicity in human hepatocellular carcinoma cells in vitro via disruption of Hsp90 function

(2021) Ahmed Attia Ahmed Abdelmoaty et al.   ACTA PHARMACOLOGICA SINICA

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations

(2021) Alan L. Ho et al.   JOURNAL OF CLINICAL ONCOLOGY

The origins and genetic interactions of KRAS mutations are allele- and tissue-specific

(2021) Joshua H. Cook et al.   Nature Communications

Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment

(2021) D. Lucas Kerr et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials

(2021) Yihui Song et al.   PHARMACOLOGY & THERAPEUTICS

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

(2020) Patrick Brown et al.   Journal of the National Comprehensive Cancer Network

Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles

(2020) Yun Bian et al.   Drug Design Development and Therapy

Mutations That Confer Drug-Resistance, Oncogenicity and Intrinsic Activity on the ERK MAP Kinases—Current State of the Art

(2020) Karina Smorodinsky-Atias et al.   Cells

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

(2020) Ufuk Degirmenci et al.   Cells

Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells

(2020) Xu Yao et al.   ACTA PHARMACOLOGICA SINICA

Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation

(2020) SHUNSAKU MIYAUCHI et al.   ANTICANCER RESEARCH

Targeting the MAPK Pathway in KRAS-Driven Tumors

(2020) Matthias Drosten et al.   CANCER CELL

The Frequency of Ras Mutations in Cancer

(2020) Ian A. Prior et al.   CANCER RESEARCH

Strategies of Human T-Cell Leukemia Virus Type 1 for Persistent Infection: Implications for Leukemogenesis of Adult T-Cell Leukemia-Lymphoma

(2020) Jun-ichirou Yasunaga   Frontiers in Microbiology

BRAF mutation and its inhibitors in sarcoma treatment

(2020) Haotian Liu et al.   Cancer Medicine

A perspective on the early days of RAS research

(2020) Robin A. Weiss   CANCER AND METASTASIS REVIEWS

Leveraging systematic functional analysis to benchmark an in silico framework distinguishes driver from passenger MEK mutants in cancer

(2020) Aphrothiti J. Hanrahan et al.   CANCER RESEARCH

RAS-targeted therapies: is the undruggable drugged?

(2020) Amanda R. Moore et al.   NATURE REVIEWS DRUG DISCOVERY

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

(2020) João M. Fernandes Neto et al.   Nature Communications

Dimerization Induced by C-Terminal 14–3–3 Binding Is Sufficient for BRAF Kinase Activation

(2020) Nicholas P.D. Liau et al.   BIOCHEMISTRY

Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer

(2020) Yuta Adachi et al.   CLINICAL CANCER RESEARCH

Curcumin and Photobiomodulation in Chronic Viral Hepatitis and Hepatocellular Carcinoma

(2020) Laura Marinela Ailioaie et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy

(2020) Jimin Yuan et al.   Journal of Hematology & Oncology

BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition

(2020) Marco H Hofmann et al.   Cancer Discovery

MEK inhibitor resistance mechanisms and recent developments in combination trials

(2020) E. Kun et al.   CANCER TREATMENT REVIEWS

Hepatocellular carcinoma: old friends and new tricks

(2020) Eunsun Kim et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

The 14-3-3 Proteins as Important Allosteric Regulators of Protein Kinases

(2020) Veronika Obsilova et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer

(2020) Priyanka Ray et al.   MOLECULAR PHARMACEUTICS

Identification of clinical molecular targets for childhood Burkitt lymphoma

(2020) Jing Zhang et al.   Translational Oncology

Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer

(2019) Kirsten L. Bryant et al.   NATURE MEDICINE

Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019

(2019) Margaret A. Tempero et al.   Journal of the National Comprehensive Cancer Network

MEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells

(2019) Huanji Xu et al.   CELL DEATH AND DIFFERENTIATION

The Sprouty/Spred family as tumor suppressors: Coming of age

(2019) Tetsuro Kawazoe et al.   CANCER SCIENCE

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

(2019) Paolo Strati et al.   HAEMATOLOGICA

GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation

(2019) Michael Dougan et al.   IMMUNITY

GPR31 and GPR151 are activated under acidic conditions

(2019) Misaki Mashiko et al.   JOURNAL OF BIOCHEMISTRY

Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer–stromal interaction and metastasis

(2019) Zilong Yan et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Hepatocellular Carcinoma

(2019) Augusto Villanueva   NEW ENGLAND JOURNAL OF MEDICINE

K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling

(2019) Qing Yin et al.   Nature Communications

The Ras Superfamily of Small GTPases in Non-neoplastic Cerebral Diseases

(2019) Liang Qu et al.   Frontiers in Molecular Neuroscience

CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC.

(2019) Jeffrey H Becker et al.   CANCER RESEARCH

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

(2019) Martin S. Tallman et al.   Journal of the National Comprehensive Cancer Network

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

(2019) Antoni Ribas et al.   NATURE MEDICINE

miR-1307-3p promotes tumor growth and metastasis of hepatocellular carcinoma by repressing DAB2 interacting protein

(2019) Shuangjiang Chen et al.   BIOMEDICINE & PHARMACOTHERAPY

Current state of melanoma diagnosis and treatment

(2019) Lauren E. Davis et al.   CANCER BIOLOGY & THERAPY

Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

(2019) Narjust Duma et al.   MAYO CLINIC PROCEEDINGS

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020

(2019) Robert J. Motzer et al.   Journal of the National Comprehensive Cancer Network

ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine

(2019) Shripad V Bhagwat et al.   MOLECULAR CANCER THERAPEUTICS

Architecture of autoinhibited and active BRAF–MEK1–14-3-3 complexes

(2019) Eunyoung Park et al.   NATURE

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

(2019) Jill Hallin et al.   Cancer Discovery

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020

(2019) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling

(2019) Elizabeth M. Terrell et al.   MOLECULAR CELL

Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancers

(2018) Brian R. Untch et al.   CANCER RESEARCH

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

(2018) Matthew R. Janes et al.   CELL

ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy

(2018) Bijay S. Jaiswal et al.   CLINICAL CANCER RESEARCH

Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT

(2018) Jie Mao et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer

(2018) Eric Van Cutsem et al.   INTERNATIONAL JOURNAL OF CANCER

The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking the phospho-Ser-621 in the carboxyl-terminus of CRAF

(2018) Jimin Yuan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines

(2018) Jin Sun Kim et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities

(2018) Manuela Porru et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples

(2018) Claudia M. Wever et al.   LEUKEMIA & LYMPHOMA

Check point inhibitors a new era in renal cell carcinoma treatment

(2018) Mohamed Alsharedi et al.   MEDICAL ONCOLOGY

The dynamic and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent protein–protein interactions

(2018) KL Pennington et al.   ONCOGENE

Myelodysplastic syndromes current treatment algorithm 2018

(2018) David P. Steensma   Blood Cancer Journal

Bladder Cancer: New Insights into Its Molecular Pathology

(2018) Kentaro Inamura   Cancers

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

(2018) Jerald P. Radich et al.   Journal of the National Comprehensive Cancer Network

Molecular mechanisms of viral oncogenesis in humans

(2018) Nathan A. Krump et al.   NATURE REVIEWS MICROBIOLOGY

Adult T Cell Leukemia-Lymphoma (ATL): State of the Art

(2018) Adrienne A. Phillips et al.   Current Hematologic Malignancy Reports

Diagnosis and Treatment of Ovarian Cancer

(2018) Brian Orr et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer

(2018) Marcel Wiesweg et al.   ONCOGENE

SHOC2–MRAS–PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis

(2018) Lucy C. Young et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

(2017) Matthew A. Coelho et al.   IMMUNITY

RAS and PD-L1: A Masters’ Liaison in Cancer Immune Evasion

(2017) Nicole Glodde et al.   IMMUNITY

The G protein–coupled receptor GPR31 promotes membrane association of KRAS

(2017) Nicole Fehrenbacher et al.   JOURNAL OF CELL BIOLOGY

HTLV-1 Infection and Neuropathogenesis in the Context of Rag1-/-γc-/- (RAG1-Hu) and BLT Mice

(2017) Rashida Ginwala et al.   Journal of Neuroimmune Pharmacology

Pancreatic cancer heterogeneity and response to Mek inhibition

(2017) K Pedersen et al.   ONCOGENE

Evaluation of K-ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas

(2017) Liming Lu et al.   PLoS One

New tricks for human farnesyltransferase inhibitor: cancer and beyond

(2017) Jingyuan Wang et al.   MedChemComm

Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer

(2017) Changwen Ning et al.   Oncotarget

Roles of Rap1 signaling in tumor cell migration and invasion

(2017) Zhang Yi-Lei et al.   Cancer Biology & Medicine

Adult T-Cell Leukemia/Lymphoma

(2017) Neha Mehta-Shah et al.   Journal of Oncology Practice

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression

(2016) Tikvah K. Hayes et al.   CANCER CELL

Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF–CRAF Heterodimerization

(2016) Lise Boussemart et al.   CANCER RESEARCH

Metabolic Heterogeneity in Human Lung Tumors

(2016) Christopher T. Hensley et al.   CELL

Negative feedback regulation of the ERK1/2 MAPK pathway

(2016) David Lake et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Prognostic and predictive markers in pancreatic adenocarcinoma

(2016) Nha Le et al.   DIGESTIVE AND LIVER DISEASE

Update on Burkitt Lymphoma

(2016) Kieron Dunleavy et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

RAS isoforms and mutations in cancer at a glance

(2016) G. Aaron Hobbs et al.   JOURNAL OF CELL SCIENCE

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

(2016) Peter L. Greenberg et al.   Journal of the National Comprehensive Cancer Network

Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?

(2016) Sandra Cristea et al.   Journal of Thoracic Oncology

How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization

(2016) Ethan J. Brock et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities

(2016) Emma M. Kerr et al.   NATURE

Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ

(2016) Srisathiyanarayanan Dharmaiah et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC

(2016) Lei Li et al.   Oncology Letters

Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia

(2016) M M Patnaik et al.   Blood Cancer Journal

Galectin-1 dimers can scaffold Raf-effectors to increase H-ras nanoclustering

(2016) Olga Blaževitš et al.   Scientific Reports

Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells

(2016) S. Zdanov et al.   Cancer Immunology Research

Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells

(2015) S. Martin et al.   BIOCHEMICAL PHARMACOLOGY

Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

(2015) A. D. Cox et al.   CLINICAL CANCER RESEARCH

A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer

(2015) Bengt Gustavsson et al.   Clinical Colorectal Cancer

New RAS-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma

(2015) Matteo S. Carlino et al.   JOURNAL OF CLINICAL ONCOLOGY

Recent advances in RASopathies

(2015) Yoko Aoki et al.   JOURNAL OF HUMAN GENETICS

Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis

(2015) Yu Sun et al.   JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION

Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas

(2015) Helena A. Yu et al.   Journal of Thoracic Oncology

Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: A case report

(2015) Wouter W. Mellema et al.   LUNG CANCER

The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses

(2015) Lifang Zhang et al.   Molecular Cancer

Integrated molecular analysis of adult T cell leukemia/lymphoma

(2015) Keisuke Kataoka et al.   NATURE GENETICS

Regulation of RAF protein kinases in ERK signalling

(2015) Hugo Lavoie et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myocyte enhancer factor (MEF)-2 plays essential roles in T-cell transformation associated with HTLV-1 infection by stabilizing complex between Tax and CREB

(2015) Pooja Jain et al.   Retrovirology

Analysis of the prognosis of patients with testicular seminoma

(2015) WEI DONG et al.   Oncology Letters

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

(2015) Agnieszka K. Witkiewicz et al.   Nature Communications

Treating Burkitt Lymphoma in Adults

(2015) Carla Casulo et al.   Current Hematologic Malignancy Reports

How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)?

(2015) Charles RM Bangham et al.   Current Opinion in Virology

BRAF gene: From human cancers to developmental syndromes

(2015) Muhammad Ramzan Manwar Hussain et al.   SAUDI JOURNAL OF BIOLOGICAL SCIENCES

Trouble at the core: BRAF(V600E) drives multiple modes of T-cell suppression in melanoma

(2015) Sherille D. Bradley et al.   OncoImmunology

Pancreatic Adenocarcinoma

(2015) David P. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRAFkinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-typeRAS

(2014) Liping Zhang et al.   AMERICAN JOURNAL OF HEMATOLOGY

Hepatocellular carcinoma epidemiology

(2014) Cristina Bosetti et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Modeling the Role of G12V and G13V Ras Mutations in the Ras-GAP-Catalyzed Hydrolysis Reaction of Guanosine Triphosphate

(2014) Maria G. Khrenova et al.   BIOCHEMISTRY

Cancer treatment and survivorship statistics, 2014

(2014) Carol E. DeSantis et al.   CA-A CANCER JOURNAL FOR CLINICIANS

ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors

(2014) E. M. Goetz et al.   CANCER RESEARCH

Human Viral Oncogenesis: A Cancer Hallmarks Analysis

(2014) Enrique A. Mesri et al.   Cell Host & Microbe

Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival

(2014) Lisa Pleyer et al.   LEUKEMIA RESEARCH

The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatitis B virus infection and aflatoxin B1 exposure

(2014) Lu-Nan Qi et al.   LIVER INTERNATIONAL

Protein interaction switches coordinate Raf-1 and MST2/Hippo signalling

(2014) David Romano et al.   NATURE CELL BIOLOGY

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway

(2014) Matthias Drosten et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma

(2014) WENMIN HOU et al.   Oncology Letters

HTLV-1 Tax-Mediated Inhibition of FOXO3a Activity Is Critical for the Persistence of Terminally Differentiated CD4+ T Cells

(2014) David Olagnier et al.   PLoS Pathogens

Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting

(2014) Thomas Knight et al.   Frontiers in Oncology

Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) J. Oldenburg et al.   ANNALS OF ONCOLOGY

Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis

(2013) Firas Abdollah et al.   Cancer Epidemiology

Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers

(2013) Jiancheng Hu et al.   CELL

Pooled Analysis of the Prognostic and Predictive Effects ofKRASMutation Status andKRASMutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy

(2013) Frances A. Shepherd et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis

(2013) Daquan Meng et al.   LUNG CANCER

Phosphorylation of BRAF by AMPK Impairs BRAF-KSR1 Association and Cell Proliferation

(2013) Che-Hung Shen et al.   MOLECULAR CELL

Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma

(2013) Geoffrey T. Gibney et al.   Nature Reviews Clinical Oncology

PAG - a multipurpose transmembrane adaptor protein

(2013) M Hrdinka et al.   ONCOGENE

Emerging targets in cancer management: role of the CXCL12/CXCR4 axis

(2013) Anna Dubrovska et al.   OncoTargets and Therapy

The Basic Principles of Chimeric Antigen Receptor Design

(2013) Michel Sadelain et al.   Cancer Discovery

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

(2013) E. M. Van Allen et al.   Cancer Discovery

Epidemiology of Myelodysplastic Syndromes

(2012) Xiaomei Ma   AMERICAN JOURNAL OF MEDICINE

Clinical and proteomic characterization of acute myeloid leukemia with mutatedRAS

(2012) Tapan M. Kadia et al.   CANCER

Targeting the Ras–ERK pathway in pancreatic adenocarcinoma

(2012) Cindy Neuzillet et al.   CANCER AND METASTASIS REVIEWS

Obesity and Ovarian Cancer Survival: A Systematic Review and Meta-analysis

(2012) M. M. Protani et al.   Cancer Prevention Research

A Comprehensive Survey of Ras Mutations in Cancer

(2012) I. A. Prior et al.   CANCER RESEARCH

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

(2012) J. S. Khalili et al.   CLINICAL CANCER RESEARCH

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

(2012) S. Dogan et al.   CLINICAL CANCER RESEARCH

The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling

(2012) Sophie E. Broughton et al.   IMMUNOLOGICAL REVIEWS

Activation of ras-dependent signaling pathways by G14-coupled receptors requires the adaptor protein TPR1

(2012) Dawna H.T. Kwan et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

(2012) Nathan T. Ihle et al.   JNCI-Journal of the National Cancer Institute

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

(2012) Julian R. Molina et al.   MAYO CLINIC PROCEEDINGS

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

(2012) J. G. Greger et al.   MOLECULAR CANCER THERAPEUTICS

ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors

(2012) G. Hatzivassiliou et al.   MOLECULAR CANCER THERAPEUTICS

Neoplasms Associated with Germline and Somatic NF1 Gene Mutations

(2012) S. Patil et al.   ONCOLOGIST

Frequencies and Prognostic Role of KRAS and BRAF Mutations in Patients With Localized Pancreatic and Ampullary Adenocarcinomas

(2012) Nicolai Aagaard Schultz et al.   PANCREAS

Ras and GTPase-activating protein (GAP) drive GTP into a precatalytic state as revealed by combining FTIR and biomolecular simulations

(2012) T. Rudack et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A rare point mutation in the Ras oncogene in hepatocellular carcinoma

(2012) Akinobu Taketomi et al.   SURGERY TODAY

The Cyclic AMP Pathway

(2012) P. Sassone-Corsi   Cold Spring Harbor Perspectives in Biology

Molecular Hallmarks of Adult T Cell Leukemia

(2012) Makoto Yamagishi et al.   Frontiers in Microbiology

Ras signaling contributes to survival of human T-cell leukemia/lymphoma virus type 1 (HTLV-1) Tax-positive T-cells

(2011) Giovanna Stoppa et al.   APOPTOSIS

c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma

(2011) Rafael B. Blasco et al.   CANCER CELL

Combinatorial Treatments That Overcome PDGFR -Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition

(2011) H. Shi et al.   CANCER RESEARCH

Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-RafV600E Mutation

(2011) H. Wang et al.   CANCER RESEARCH

Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma

(2011) L. Chen et al.   EJSO

Low expression of DAB2IP contributes to malignant development and poor prognosis in hepatocellular carcinoma

(2011) Xiaojing Zhang et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation

(2011) Roberto Gedaly et al.   JOURNAL OF SURGICAL RESEARCH

Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasion

(2011) H Feng et al.   ONCOGENE

C-Raf Is Required for the Initiation of Lung Cancer by K-Ras G12D

(2011) Florian A. Karreth et al.   Cancer Discovery

Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience

(2011) Thomas J. Semrad et al.   Therapeutic Advances in Medical Oncology

The RasGrf family of mammalian guanine nucleotide exchange factors

(2010) Alberto Fernández-Medarde et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH

Murine FLT3 Ligand-Derived Dendritic Cell-Mediated Early Immune Responses Are Critical to Controlling Cell-Free Human T Cell Leukemia Virus Type 1 Infection

(2010) S. Rahman et al.   JOURNAL OF IMMUNOLOGY

An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB

(2010) Junxia Min et al.   NATURE MEDICINE

K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function

(2010) B Alvarez-Moya et al.   ONCOGENE

Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis

(2010) D. Xie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Proteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in Gliomagenesis

(2009) Lauren T. McGillicuddy et al.   CANCER CELL

Sorafenib Inhibits Non-Small Cell Lung Cancer Cell Growth by Targeting B-RAF in KRAS Wild-Type Cells and C-RAF in KRAS Mutant Cells

(2009) K. Takezawa et al.   CANCER RESEARCH

Tax1 enhances cancer cell proliferation via Ras-Raf-MEK-ERK signaling pathway

(2009) Chunjiao Song et al.   IUBMB LIFE

Influence of the Lipidation Motif on the Partitioning and Association of N-Ras in Model Membrane Subdomains

(2009) Katrin Weise et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

DC-SIGN Mediates Cell-Free Infection and Transmission of Human T-Cell Lymphotropic Virus Type 1 by Dendritic Cells

(2009) P. Jain et al.   JOURNAL OF VIROLOGY

Ras acylation, compartmentalization and signaling nanoclusters (Review)

(2009) Yoav I. Henis et al.   MOLECULAR MEMBRANE BIOLOGY

MEK1 mutations confer resistance to MEK and B-RAF inhibition

(2009) C. M. Emery et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protein-tyrosine kinase CAKβ/PYK2 is activated by binding Ca2+/calmodulin to FERM F2 α2 helix and thus forming its dimer

(2008) Takayuki Kohno et al.   BIOCHEMICAL JOURNAL

Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1genes

(2008) Véronique Gelsi-Boyer et al.   BMC CANCER

Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer

(2008) C. A. Pratilas et al.   CANCER RESEARCH

ras oncogenes: their role in neoplasia

(2008) M. BARBACID   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation

(2008) Majid Momeny et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Patients With Acute Myeloid Leukemia andRASMutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study

(2008) Andreas Neubauer et al.   JOURNAL OF CLINICAL ONCOLOGY

Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells

(2008) X Sui et al.   ONCOGENE